Lonza, the world’s leading contract development and manufacturing organization (CDMO), will participate in the Jefferies Global Healthcare Conference in London on 17 and 18 November 2026. As part of the conference, CEO Wolfgang Wienand will host a presentation and subsequent Q&A on 18 November from 15:30 to 15:55 GMT (16:30 to 16:55 CET). The session will be webcast live, and a replay will be available on the Lonza Investor Relations website, remaining accessible for 90 days. The live audio webcast can be accessed via this link.
The announcement matters because Lonza occupies a critical position in the global healthcare supply chain. As a CDMO, it works alongside pharma and biotech companies to turn breakthrough innovations into viable therapies, enabling customers to bring life-saving and life-enhancing treatments to patients worldwide. With approximately 17,000 colleagues across three continents, Lonza combines cutting-edge science, smart technology and lean manufacturing to support drug development and production. For investors and industry observers, Wienand’s presentation offers a timely window into the company’s performance and priorities.
Lonza’s scale is reflected in its recent financial results. The company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Those figures underscore the company’s role as a major player in the healthcare industry and explain why its leadership appearances draw attention. The Jefferies conference, a prominent gathering of healthcare investors and executives, provides a forum for Lonza to discuss its business outlook and the trends shaping the CDMO sector.
For readers, the implications extend beyond a single conference session. Lonza’s work supports the development and manufacturing of therapies that reach patients globally, so its strategic direction can influence the pace and availability of new treatments. The company’s global team and manufacturing footprint mean that its operational decisions can affect pharmaceutical and biotech customers across three continents. More information about Lonza is available at www.lonza.com.
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (SGX-ST). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. The webcast and replay give investors who cannot attend in London a chance to hear directly from Wienand, with the replay remaining accessible for 90 days after the event. The original release can be viewed on www.newmediawire.com.
